You have free access to this content

Cancer

Cover image for Cancer

15 December 2006

Volume 107, Issue 12

Pages 2745–2960

  1. Original Articles

    1. Top of page
    2. Original Articles
    3. Correspondence
    4. Erratum
    1. Disease Site

      Breast Disease
      You have free access to this content
      Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing : A single-institution study (pages 2745–2751)

      Anne Uyei, Susan K. Peterson, Julie Erlichman, Kristine Broglio, Sandra Yekell, Kathkeen Schmeler, Karen Lu, Funda Meric-Bernstam, Chris Amos, Louise Strong and Banu Arun

      Article first published online: 15 NOV 2006 | DOI: 10.1002/cncr.22352

      Little is known about clinical, demographic, or cancer-related factors associated with risk-reduction interventions for women with BRCA mutations. The current study found that women who were BRCA carriers, women who had a history of breast cancer, DCIS, or breast biopsy, or had a family history of ovarian cancer were more likely to have undergone surgery for cancer risk reduction. Women with ovarian cancer or advanced breast cancer were more likely to have undergone surveillance.

    2. Endocrine Disease
      You have free access to this content
      RIZ1 is epigenetically inactivated by promoter hypermethylation in thyroid carcinoma (pages 2752–2759)

      Geeta Lal, Lakshmi Padmanabha, Brian J. Smith, Rachael M. Nicholson, James R. Howe, M. Sue O'Dorisio and Frederick E. Domann Jr

      Article first published online: 13 NOV 2006 | DOI: 10.1002/cncr.22325

      RIZ1 expression is lost in thyroid tumor cell lines and is also significantly reduced in thyroid carcinomas, when compared with normal thyroid tissues and benign tumors. The current study results show that loss of RIZ1 is mediated by aberrant cytosine methylation of the RIZ1 promoter.

    3. Gastrointestinal Tract
      You have free access to this content
      A recombinant human RNASET2 glycoprotein with antitumorigenic and antiangiogenic characteristics : Expression, purification, and characterization (pages 2760–2769)

      Patricia Smirnoff, Levava Roiz, Boaz Angelkovitch, Betty Schwartz and Oded Shoseyov

      Article first published online: 15 NOV 2006 | DOI: 10.1002/cncr.22327

      Human RNASET2 gene was cloned into Pichia pastoris. The recombinant 27-kilodalton glycoprotein RNASET2 inhibited colony formation in HT29 cells and induced tube formation in human umbilical vein endothelial cells. In athymic mice, RNASET2 inhibited LS174T xenograft tumor development. A synergistic effect was observed when RNASET2 was applied in combination with paclitaxel, emphasizing the advantage of RNASET2 in combined anticancer therapy.

    4. You have free access to this content
      Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma : A clinicopathologic and molecular study with reference to antibiotic treatment (pages 2770–2778)

      Shotaro Nakamura, Takayuki Matsumoto, Hongtao Ye, Shigeo Nakamura, Hiroshi Suekane, Hiroshi Matsumoto, Takashi Yao, Masazumi Tsuneyoshi, Ming-Qing Du and Mitsuo Iida

      Article first published online: 10 NOV 2006 | DOI: 10.1002/cncr.22326

      Clinicopathologic and molecular findings were compared between patients with Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue (MALT) lymphoma (n = 12) and patients with H. pylori-positive tumor (n = 125). H. pylori-negative MALT lymphoma is characterized by frequent t(11;18)(q21;q21); however, antibiotic treatment should be considered also for this disease.

    5. Genitourinary Disease
      You have free access to this content
      Metastatic disease of screen-detected prostate cancer : Characteristics at diagnosis (pages 2779–2785)

      Stijn Roemeling, Ries Kranse, André N. Vis, Claartje Gosselaar, Theo H. van der Kwast and Fritz H. Schröder

      Article first published online: 15 NOV 2006 | DOI: 10.1002/cncr.22374

      Metastases of screen-detected prostate cancer are relatively rare during both diagnosis and follow-up. Individual predictors for the development of metastases are the prostate-specific antigen (PSA) level, the number of biopsy cores involved with prostate cancer, and the biopsy Gleason score.

    6. Gynecologic Oncology
      You have free access to this content
      Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma : A Gynecologic Oncology Group study (pages 2786–2791)

      Vivian E. von Gruenigen, Chunqiao Tian, Heidi Frasure, Steven Waggoner, Henry Keys and Richard R. Barakat

      Article first published online: 9 NOV 2006 | DOI: 10.1002/cncr.22351

      In early stage endometrial cancer patients, obesity was associated with decreased survival but not disease recurrence. Recommended is a future study exploring the influence of weight loss on survival in this patient population.

    7. Head and Neck Disease
      You have free access to this content
      Critical evaluation of frozen section margins in head and neck cancer resections (pages 2792–2800)

      Candice Black, Jonathan Marotti, Elena Zarovnaya and Joseph Paydarfar

      Article first published online: 21 NOV 2006 | DOI: 10.1002/cncr.22347

      The Toyota principles of quality improvement reveal possible areas of error, waste, and redundancy in the current system of reporting of final head and neck cancer resection margins. Many system failures are due to a lack of anatomic correlation at interdisciplinary hand-offs.

    8. Hematologic Malignancies
      You have free access to this content
      Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia (pages 2801–2806)

      Kathrin Strasser-Weippl, Michael Steurer, Mathias Kees, Florian Augustin, Alexandar Tzankov, Stephan Dirnhofer, Michael Fiegl, Ingrid Simonitsch-Klupp, Heinz Gisslinger, Niklas Zojer and Heinz Ludwig

      Article first published online: 13 NOV 2006 | DOI: 10.1002/cncr.22318

      Using fluorescence in situ hybridization, cytogenetic abnormalities can be detected reliably in patients with myelofibrosis. The most frequent aberrations are not associated with prognosis in this disease.

    9. You have free access to this content
      Darbepoetin α for the treatment of anemia in patients with myelodysplastic syndromes (pages 2807–2816)

      Pilar Giraldo, Benet Nomdedeu, Javier Loscertales, Carmen Requena, Raquel de Paz, Mar Tormo, Pilar Navarro, Patricia Benedit, José Antonio Gasquet and on behalf of the Aranesp in Myelodysplastic Syndromes (ARM) Study Group

      Article first published online: 17 NOV 2006 | DOI: 10.1002/cncr.22343

      The authors conducted a retrospective analysis of 81 patients with myelodysplastic syndrome (MDS) who were enrolled at 9 Spanish centers. All patients had received weekly darbepoetin α (DA) (75–300 μg) for 16 weeks. The results supported the safety, efficacy, and tolerability profile of DA as treatment for MDS-induced anemia, and larger prospective studies with long-term follow-up and health-related quality-of-life assessments are warranted.

    10. You have free access to this content
      Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma : Results of Cancer and Leukemia Group B Study 9153 (pages 2817–2825)

      Kristie A. Blum, Jeffrey L. Johnson, Donna Niedzwiecki, Lawrence D. Piro, Alan Saven, Bruce A. Peterson, John C. Byrd, Bruce D. Cheson and for the Cancer and Leukemia Group B

      Article first published online: 21 NOV 2006 | DOI: 10.1002/cncr.22344

      In this multiinstitutional trial of single-agent 2-chlorodeoxyadenosine for patients with previously untreated, low-grade lymphoma, 38 patients were eligible. The overall response rate was 100% (complete response rate, 31.6%). The median failure-free survival was 2 years, and overall survival was 7 years. Toxicity consisted primarily of myelosuppression with few infections. There were 4 late malignancies, and 4 patients with large cell transformation were reported.

    11. You have free access to this content
      A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma (pages 2826–2832)

      Ivana N. M. Micallef, Brad S. Kahl, Matthew J. Maurer, Ahmet Dogan, Stephen M. Ansell, Joseph P. Colgan, Susan Geyer, David J. Inwards, William L. White and Thomas M. Habermann

      Article first published online: 10 NOV 2006 | DOI: 10.1002/cncr.22342

      In this pilot study of combined chemotherapy with epratuzumab and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (ER-CHOP) in patients with newly diagnosed, diffuse largeB-cell lymphoma, the treatment was tolerated well and appeared promising. At a median follow-up of 30 months, 13 of 15 patients remained alive. The 1-year progression-free and overall survival rates were 93% and 100%, respectively, and the respective 2-year rates were 86% and 86%. A Phase II multicenter study currently is underway.

    12. Hepatobiliary Tract
      You have free access to this content
      Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors : Response, survival, and prognostic factors (pages 2833–2841)

      Katsuhiro Kobayashi, Sanjay Gupta, Jonathan C. Trent, Jean-Nicolas Vauthey, Savitri Krishnamurthy, Joe Ensor, Kamran Ahrar, Michael J. Wallace, David C. Madoff, Ravi Murthy, Stephen E. McRae and Marshall E. Hicks

      Article first published online: 9 NOV 2006 | DOI: 10.1002/cncr.22336

      In a retrospective study, hepatic artery chemoembolization (HACE) induced durable tumor response or disease stabilization in patients with gastrointestinal stromal tumors metastatic to the liver. Multiple factors including extent of the liver disease, presence of extrahepatic disease, number of embolization treatments, and use of imatinib were found to have a prognostic influence on survival after HACE.

    13. Lung Disease
      You have free access to this content
      Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer (pages 2842–2849)

      Andrea Ardizzoni, Mara A. Cafferata, Marcello Tiseo, Rosangela Filiberti, Paola Marroni, Francesco Grossi and Michela Paganuzzi

      Article first published online: 13 NOV 2006 | DOI: 10.1002/cncr.22330

      The authors report the original results from a study in which they investigated the role of decline in the levels of carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA 21-1) during chemotherapy as a surrogate marker of treatment outcome in patients with advanced nonsmall cell lung cancer (NSCLC). The results support the proposal of using the measurement of serial serum markers, particularly CYFRA 21-1, during first-line chemotherapy for advanced NSCLC to assess treatment outcomes, to define prognosis better, and to make decisions about further treatments.

    14. You have free access to this content
      Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer (pages 2850–2857)

      Guillermo Gervasini, Juan Antonio Carrillo, Montserrat Garcia, Carmen San Jose, Agustin Cabanillas and Julio Benitez

      Article first published online: 21 NOV 2006 | DOI: 10.1002/cncr.22332

      The existence of polymorphisms in the P-glycoprotein that encode the multidrug resistance 1 gene (adenosine triphosphate-binding cassette B1) and, specifically, the presence of the G2677T single-nucleotide polymorphism can be crucial in conferring susceptibility to lung cancer. In this study, squamous cell carcinoma appeared to be the lung cancer type associated most strongly with the presence of these allelic variants.

    15. You have free access to this content
      Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer (pages 2858–2865)

      Victor Cohen, Jason S. Agulnik, Jonathan Jarry, Gerald Batist, David Small, Harvey Kreisman, Neely Adriana Tejada, Wilson H. Miller Jr and George Chong

      Article first published online: 9 NOV 2006 | DOI: 10.1002/cncr.22331

      Denaturing high-performance liquid chromatography (dHPLC) is an efficient and more sensitive method for screening for genomic alterations in exons 19 and 21 of the EGFR gene compared with direct sequence analysis. These data suggest that dHPLC should be implemented as a screening tool for the detection of EGFR mutations.

    16. You have free access to this content
      Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients (pages 2866–2872)

      Rebecca P. Petersen, Michael J. Campa, Justin Sperlazza, Debbi Conlon, Mary-Beth Joshi, David H. Harpole Jr and Edward F. Patz Jr

      Article first published online: 10 NOV 2006 | DOI: 10.1002/cncr.22282

      Regulatory T-cells represent a subset of total tumor-infiltrating T lymphocytes and are present in various amounts in pathologic stage I NSCLC tumors. Early stage lung cancers that have a greater proportion of regulatory T-cells relative to total tumor-infiltrating T lymphocytes have a significantly higher risk of recurrence.

    17. You have free access to this content
      Risk factors for local progression after percutaneous radiofrequency ablation of lung tumors : Evaluation based on a preliminary review of 342 tumors (pages 2873–2880)

      Takao Hiraki, Jun Sakurai, Toshihide Tsuda, Hideo Gobara, Yoshifumi Sano, Takashi Mukai, Soichiro Hase, Toshihiro Iguchi, Hiroyasu Fujiwara, Hiroshi Date and Susumu Kanazawa

      Article first published online: 9 NOV 2006 | DOI: 10.1002/cncr.22333

      Larger tumor size and the use of an internally cooled electrode were determined to be independent risk factors for local progression after radiofrequency (RF) ablation of lung tumors. RF ablation of lung tumors smaller than 2 cm and their treatment with a multitined expandable electrode enabled favorable local tumor control.

    18. Sarcoma
      You have free access to this content
      Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy (pages 2881–2887)

      Shreyaskumar Patel, Mary Louise Keohan, M. Wasif Saif, Daniel Rushing, Luis Baez, Kevie Feit, Robert DeJager and Sibyl Anderson

      Article first published online: 15 NOV 2006 | DOI: 10.1002/cncr.22334

      TZT-1027, a novel antimitotic agent, was tested in patients with soft-tissue sarcomas. In all, 21% of patients experienced stable disease but no objective responses were noted. The drug was safe and well tolerated.

    19. Discipline

      Clinical Trials
      You have free access to this content
      Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis (pages 2888–2897)

      Johan Maertens, Axel Glasmacher, Raoul Herbrecht, Anne Thiebaut, Catherine Cordonnier, Brahm H. Segal, John Killar, Arlene Taylor, Nicholas Kartsonis, Thomas F. Patterson and Caspofungin Combination Therapy Study Group

      Article first published online: 13 NOV 2006 | DOI: 10.1002/cncr.22348

      Combination therapy involving caspofungin and other antifungal agents was effective and generally well tolerated as salvage therapy in patients with invasive aspergillosis. Combination therapy was associated with favorable outcomes in many patients with an expected poor prognosis.

    20. Medical Oncology
      You have free access to this content
      Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : Results of an Italian Multicenter, randomized, phase II study (pages 2898–2905)

      Sergio Palmeri, Vito Lorusso, Laura Palmeri, Marina Vaglica, Camillo Porta, Rolando Nortilli, Francesco Ferraú, Giuseppe Comella, Bruno Massidda and Marco Danova

      Article first published online: 15 NOV 2006 | DOI: 10.1002/cncr.22379

      A randomized Phase II study of cisplatin/gemcitabine plus either vinorelbine or paclitaxel in patients with carcinomas of unknown primary site was performed. Although both treatments proved to be active, according to a pick the winner attitude, the combination of cisplatin, gemcitabine, and vinorelbine should be considered in experimental arms in future randomized, Phase III trials.

    21. Pediatric Oncology
      You have free access to this content
      Population-based study of renal cell carcinoma in children in Germany, 1980–2005 : More frequently localized tumors and underlying disorders compared with adult counterparts (pages 2906–2914)

      Barbara Selle, Rhoikos Furtwängler, Norbert Graf, Peter Kaatsch, Elisabeth Bruder and Ivo Leuschner

      Article first published online: 15 NOV 2006 | DOI: 10.1002/cncr.22346

      Pediatric renal cell carcinomas are predominantly localized and frequently associated with underlying disorders. Survival rates are favorable.

    22. Psychosocial Oncology
      You have free access to this content
      Assessing the health care needs of adolescent and young adult cancer patients and survivors (pages 2915–2923)

      Brad Zebrack, Archie Bleyer, Karen Albritton, Sandra Medearis and Julia Tang

      Article first published online: 13 NOV 2006 | DOI: 10.1002/cncr.22338

      Using a modified Delphi method, oncology professionals and young adult cancer survivors identified health care needs that were specific to a population of patients/survivors who were diagnosed between ages 15 years and 35 years. Findings suggest areas in which to target investments of resources to promote quality health care and appropriate informational and supportive care services.

    23. You have free access to this content
      Distress, psychiatric syndromes, and impairment of function in women with newly diagnosed breast cancer (pages 2924–2931)

      Mark T. Hegel, Caroline P. Moore, E. Dale Collins, Stephen Kearing, Karen L. Gillock, Raine L. Riggs, Kate F. Clay and Tim A. Ahles

      Article first published online: 13 NOV 2006 | DOI: 10.1002/cncr.22335

      Distress and psychiatric syndromes are underexamined in newly diagnosed breast cancer patients. The authors report prevalence rates in this patient sample for clinically significant distress, psychiatric syndromes, and health-related function at the time of presurgical consultation.

    24. Radiation Oncology
      You have free access to this content
      Estimation of the optimal brachytherapy utilization rate in the treatment of carcinoma of the uterine cervix : Review of clinical practice guidelines and primary evidence (pages 2932–2941)

      Stephen Thompson, Geoff Delaney, Gabriel Sam Gabriel, Susannah Jacob, Prabir Das and Michael Barton

      Article first published online: 15 NOV 2006 | DOI: 10.1002/cncr.22337

      The authors constructed an evidence-based model of brachytherapy (BT) use that shows that the optimal proportion of uterine cervical carcinoma cases that should be treated with BT (the optimal BTU) is 49% (range 42–50%). They performed a Patterns of Care Study for New South Wales showing that the actual BTU was 30% in 2003; whilst in the SEER areas the actual BTU was only 24% in 2001.

    25. Translational Research
      You have free access to this content
      Augmented suppression of androgen receptor signaling by a combination of α-tocopheryl succinate and methylseleninic acid (pages 2942–2948)

      Haitao Zhang, Yue Wu, Barbara Malewicz, Junxuan Lu, Song Li, James Marshall, Clement Ip and Yan Dong

      Article first published online: 21 NOV 2006 | DOI: 10.1002/cncr.22345

      Treatment of LNCaP human prostate cancer cells with a combination of α-tocopheryl succinate (αTS) and methylseleninic acid (MSA) depressed androgen receptor (AR) and prostate-specific antigen (PSA) mRNA levels by 60% and 90%, respectively. Each agent by itself was much less effective. The results suggest an opportunity to exploit the cooperativity between αTS and MSA in blocking androgen signal transduction as a means to prostate cancer control.

    26. You have free access to this content
      The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer : A pilot study (pages 2949–2957)

      Florian Strasser, J. Lynn Palmer, Leslie R. Schover, S. Wamique Yusuf, Katherine Pisters, Rena Vassilopoulou-Sellin, Beth DeGracia, Jie S. Willey and Eduardo Bruera

      Article first published online: 13 NOV 2006 | DOI: 10.1002/cncr.22339

      In this study, the authors observed that hypogonadism seemed to represent a frequent condition in patients with advanced, incurable cancer associated with mood changes, fatigue, and anorexia/cachexia-related symptoms. Autonomic dysfunction was a frequent finding in this population but had no clear correlation with symptom distress.

  2. Correspondence

    1. Top of page
    2. Original Articles
    3. Correspondence
    4. Erratum
    1. You have free access to this content
      Adult survivors of childhood cancer and unemployment : A Metaanalysis (pages 2958–2959)

      Winston W. Huh, Norman Jaffe and Giulia Ottaviani

      Article first published online: 9 NOV 2006 | DOI: 10.1002/cncr.22349

    2. You have free access to this content
      Author Reply (page 2959)

      Angela G. de Boer, Joseph H.A.M. Verbeek and Frank J.H. van Dijk

      Article first published online: 9 NOV 2006 | DOI: 10.1002/cncr.22350

  3. Erratum

    1. Top of page
    2. Original Articles
    3. Correspondence
    4. Erratum
    1. You have free access to this content

SEARCH

SEARCH BY CITATION